Therapeutic potential of ginsenoside compound K in managing tenocyte apoptosis and extracellular matrix damage in diabetic tendinopathy

Ginsenoside in the treatment of type 2 diabetes and its complications: a promising traditional chinese medicine

Type 2 diabetes mellitus (T2DM), a chronic condition commonly observed in adults, particularly among the elderly, is characterized by a dysfunctional insulin response that impairs blood glucose regulation, resulting in persistent hyperglycemia. Ginseng, a medicinal plant with significant economic value and a longstanding history of therapeutic use in Asia, has shown efficacy against various diseases. Extensive clinical and experimental studies highlight ginsenosides, its primary bioactive compounds, for their multiple therapeutic effects across a range of conditions, including endocrine, cardiovascular, and central nervous system disorders. Various ginsenoside types have demonstrated potential in lowering blood glucose levels, reducing insulin resistance, and alleviating complications through the modulation of key protein targets and signaling pathways. This review consolidates the pharmacological actions and mechanisms of distinct ginsenosides in managing diabetes and its complications, offering a theoretical foundation for further pharmacological research and novel drug development for T2DM treatment, while also providing robust theoretical support for future clinical applications.

Urolithin A attenuates apoptosis and ferroptosis in hyperlipidemic tenocytes through PPARδ/ALDH2-mediated antioxidative signaling

Urolithin A (URA), a product of the gut microflora from foods rich in ellagitannins found in berries and nuts, has demonstrated anti-inflammatory and antioxidative stress properties in various disease models. Ferroptosis, an iron-dependent form of cell death, is considered a pathogenic cause of tendinopathy. However, the effects of URA on hyperlipidemic tenocytes and the related molecular mechanisms for the treatment of tendinopathy have not been elucidated. The expression of various proteins in human primary tenocytes was assessed via Western blot analysis. Tenocyte reactive oxygen species (ROS) were detected via DCFDA staining. Apoptotic tenocytes were visualized via TUNEL staining. The activities of antioxidant enzymes and caspase 3 were measured via activity assays. Cell viability was examined via the MTT assay. In this study, we found that URA treatment blocked ferroptosis and apoptosis and improved oxidative stress in palmitate-treated tenocytes. Moreover, URA treatment reversed the changes in the expression of extracellular matrix (ECM) markers and impaired cell migration. siRNA targeting PPARδ or ALDH2 abrogated the effects of URA on tenocytes treated with palmitate. Additionally, treatment of tenocytes with URA increased SOD and catalase activities. These results suggest that URA ameliorates tenocyte ferroptosis and apoptosis through PPARδ/ALDH2 signaling-mediated suppression of oxidative stress. By utilizing natural bioactive compounds derived from renewable dietary sources, this study highlights a potential therapeutic avenue for treating obesity-related tendinopathy while emphasizing the importance of sustainable, health-promoting interventions.

A GH1 β-glucosidase from the Fervidobacterium pennivorans DSM9078 showed extraordinary thermostability and distinctive ability in the efficient transformation of ginsenosides

A novel GH1 β-glucosidase Fpglu1 from Fervidobacterium pennivorans DSM9078 was successfully cloned and expressed in Escherichia coli. This hyperthermophilic enzyme possesses unique features that make it valuable in biochemistry and pharmacology. It exhibited optimal activity at temperatures exceeding 100 °C, a trait rarely observed in other enzymes, and demonstrated extraordinary thermostability. It displayed multifunctional activity, with the highest activity observed for p-nitrophenyl-β-d-glucopyranoside (pNPGlu) at 92.47 U/mg. Furthermore, the distinctive capacity of Fpglu1 to transform ginsenosides (Rb1, Rb2, and Rc) into Compound-K (C-K) sets it apart from the other enzymes. It effectively cleaved the external β-(1-6) glycosidic linkage at the C-20 position of ginsenosides Rb1, Rb2, and Rc, followed by hydrolysis ofthe internal glycosidic bond connected to the C-3 position. The kcat/Km value of Fpglu1 for Rb1 was 453 ± 1.27 mM-1/s, significantly higher than those of Fpglu1 for other ginsenosides. The crystal structure of Fpglu1, determined at 1.85 Å resolution, provided a deeper understanding of its catalysis and substrate specificity. The evaluation of the binding conformation, hydrogen bond, and key amino acids of β-glucosidase Fpglu1 with different ginsenosides (Rb1, Rb2, and Rc) further elucidated the structural basis of its substrate-binding preference. In summary, Fpglu1, which had excellent thermostability and unique ginsenoside-transforming ability, was a highly promising catalyst for the industrial production of ginsenoside C-K. Additionally, structural studies have laid a theoretical foundation for further improving the catalytic properties of the enzyme through directed evolution in the future.

Bioconversion, Pharmacokinetics, and Therapeutic Mechanisms of Ginsenoside Compound K and Its Analogues for Treating Metabolic Diseases

Rare ginsenoside compound K (CK) is an intestinal microbial metabolite with a low natural abundance that is primarily produced by physicochemical processing, side chain modification, or metabolic transformation in the gut. Moreover, CK exhibits potent biological activity compared to primary ginsenosides, which has raised concerns in the field of ginseng research and development, as well as ginsenoside-related dietary supplements and natural products. Ginsenosides Rb1, Rb2, and Rc are generally used as a substrate to generate CK via several bioconversion processes. Current research shows that CK has a wide range of pharmacological actions, including boosting osteogenesis, lipid and glucose metabolism, lipid oxidation, insulin resistance, and anti-inflammatory and anti-apoptosis properties. Further research on the bioavailability and toxicology of CK can advance its medicinal application. The purpose of this review is to lay the groundwork for future clinical studies and the development of CK as a therapy for metabolic disorders. Furthermore, the toxicology and pharmacology of CK are investigated as well in this review. The findings indicate that CK primarily modulates signaling pathways associated with AMPK, SIRT1, PPARs, WNTs, and NF-kB. It also demonstrates a positive therapeutic effect of CK on non-alcoholic fatty liver disease (NAFLD), obesity, hyperlipidemia, diabetes, and its complications, as well as osteoporosis. Additionally, the analogues of CK showed more bioavailability, less toxicity, and more efficacy against disease states. Enhancing bioavailability and regulating hazardous variables are crucial for its use in clinical trials.